INNOVADERM CRO IS NOW INDERO.

Atopy and Alopecia Areata: A Leading Pair

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

Atopy and Alopecia Areata

Alopecia areata (AA) and atopy, which is a predisposition to develop allergic reactions, share a significant connection. While thyroid complications are often the primary concern in autoimmune diseases, a substantial number of these patients also suffer from allergies and hypersensitivities. In fact, atopic conditions are found in 30% to 50% of AA patients. 

Importance of Understanding Atopy as a Comorbidity in AA 

Interestingly, AA flares often coincide with peak allergy seasons in the spring and fall. These flares were previously attributed to changes in the season or to the stress associated with the start of the school year, but the correlation with peak allergy seasons suggests a potential link between these conditions. 

Relationship Between AD and AA

Recent studies show that AA often follows a flare of atopic dermatitis (AD), leading to the hypothesis that managing AD may also help control AA.

A case study of a patient under the care of Dr. Mesinkovska illustrates this connection. The patient, who was being treated with a strong Janus Kinase (JAK) Inhibitor for AA, experienced a flare of AD and subsequent hair loss after exposure to olive tree pollen, to which she was allergic. This case highlights the potential impact of environmental allergens on AA.

Overview of Allergies in AA Patients

allergies in alopecia areata patients

The connection between AA and allergies, previously dismissed, is now supported by emerging evidence.  

Recent research suggests the potential involvement of Immunoglobulin E (IgE) in AA. Additionally, mast cells and IgE are now recognized to play significant roles in various skin conditions, such as bullous pemphigoid, dermatitis herpetiformis, and lupus. Furthermore, studies indicate that allergies might trigger autoimmune flares, and there appears to be a link between elevated IgE levels and psoriasis. Overall, this points to a broader role for IgE in both autoimmune and skin diseases.

Significance of Eosinophils and Mast Cells

Eosinophils and mast cells, key players in allergic reactions, have been implicated in AA. Antihistamines, which target mast cells, have been used to slow the progression of AA. 

Dupilumab, a medication for AD, has shown promise as a dual treatment for both AD and AA. However, identifying the right patients and gaining access to the medication can be challenging. 

While Dupilumab can be effective at treating AA, it may cause hair loss in some cases. It can serve as a good alternative for AA patients who cannot take Jak inhibitors due to heart problems or cancer. 

The relationship between atopy and AA is complex and multifaceted. As our understanding of these conditions continues to evolve, so will our approach to treatment. Future research should continue to explore the role of allergies and atopic conditions in AA, with the goal of improving patient outcomes. 

Let’s revolutionize the research landscape and shake up the industry. Harness the power of Innovaderm for your impending trial and catapult your studies into uncharted territories.  

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.